Sun Pharma Shares Two-Year Clinical Data for LEQSELVI

93.9% of baseline responders maintained results at 108 weeks.
96.8% of non-responders achieved and maintained response by week 52.

Reader Takeaway: Positive long-term data for LEQSELVI validates the drug's safety, supporting Sun Pharma’s innovative medicine revenue growth.

What just happened

Sun Pharmaceutical Industries presented new findings for LEQSELVI (deuruxolitinib) at the 2026 EADV Congress. The data comes from a two-year open-label extension study of patients with severe alopecia areata. The study confirms that the drug, an oral JAK1 and JAK2 inhibitor, continues to show high efficacy in hair regrowth over extended periods.

Why this matters

Clinical success in dermatological treatments is a core pillar for Sun Pharma’s specialty and innovative business. By demonstrating sustained results up to 108 weeks, the company provides confidence to healthcare providers regarding the long-term utility of the drug. This aids in patient retention and market penetration for its FDA-approved product.

What changes now

Investors can expect this data to support ongoing marketing and physician education efforts. With LEQSELVI already FDA-approved, this long-term evidence acts as a clinical endorsement that could improve adoption rates within the competitive alopecia treatment market.

Risks to watch

While the company reported no major cardiovascular events in the study, JAK inhibitors remain under close regulatory scrutiny for safety profiles. Any shift in safety perceptions or emerging adverse reports in broader, real-world post-marketing use could impact future product growth.

Context metrics

The innovative medicines portfolio currently represents approximately 20% of Sun Pharma’s total global sales. The company showcased seven presentations at the EADV Congress, highlighting the importance of LEQSELVI to its future revenue mix.

What to track next

Watch for updates on market adoption rates in the US and potential regulatory progress or expansion filings for this drug in other international markets.